Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2016-02-10 Major Shareholding Noti…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2016
Major Shareholding Notification
2016-02-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 3, 2016, reporting the results of operations and financial condition for the quarter and full year ended December 31, 2015. It mentions a press release and a conference call regarding these results. The document is relatively short (3106 characters) and primarily serves as a current report to announce the earnings release and related events. It does not contain detailed financial statements or comprehensive analysis itself but references a press release and conference call. Therefore, this document fits the category of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights.
2016-02-03 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-01-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically discusses the departure of a director, Terrence Kearney, who will not run for re-election at the upcoming Annual Stockholder Meeting, and the reduction in the size of the Board. This content relates to changes in the company's board of directors. There is no financial data or report attached, and the document is not an announcement of a report publication but a direct disclosure of management/board changes. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length is 2933 characters, which is consistent with a typical 8-K filing for such an event.
2016-01-22 English
FORM 4 -
Director's Dealing
2016-01-19 English
FORM 4 -
Director's Dealing
2016-01-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.